Galderma Group stock

GALD · SIX · CHF

CHF 192.40Change from previous close: +0.52%Absolute change: +CHF 1.00

Close · November 16, 2026

Price history

+31.42% over the period

1 year: from CHF 146.40 (November 17, 2025) to CHF 192.40 (November 16, 2026), +31.42%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 16, 2026CHF 192.40
October 30, 2026CHF 192.85
September 30, 2026CHF 165.85
August 31, 2026CHF 167.90
July 31, 2026CHF 175.75
June 30, 2026CHF 183.90
May 29, 2026CHF 166.55
April 30, 2026CHF 163.80
March 31, 2026CHF 153.40
February 27, 2026CHF 145.90
January 30, 2026CHF 143.90
December 30, 2025CHF 162.10
November 28, 2025CHF 160.00
November 17, 2025CHF 146.40

At a glance

  • The company

    Develops and markets dermatology products including injectable aesthetics, skincare and therapeutic treatments worldwide

  • Latest results

    Quarter to September 30, 2026

TickerLandia's take on Galderma Group

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk lowCHF 136.30
52-wk highCHF 197.00

−2.34% from the 52-week high

Analysts · 17 analysts

Average targetCHF 210.76+9.54% vs. price

Buy 14 · Hold 2 · Sell 1 · Buy

TickerLandia Fingerprint: Galderma Group

Compared with similar companies: very low dividend and very high price.

Financials and price compared with 39 companies in the drug manufacturers - specialty & generic industry, worldwide. Momentum and risk compared with 1,160 European stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

Galderma Group is pricier than similar companies

Galderma Group's P/E (trailing 12 months): 66.0, +164% against the median of a group of 11 similar companies (25.0).

Compared with 11 similar companies

Galderma Group's metrics compared with similar companies
MetricGalderma GroupPosition in the groupBand
P/E (trailing 12 months)66.0High
Forward P/E34.7High
Operating margin19.1%Middle
ROE10.8%Middle
Debt/equity0.33Middle

Grey band: the middle half of the group; tick: the median; dot: Galderma Group. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

$3.15B

Latest quarter · Q2 2026

Net income

$444M

Latest quarter · Q2 2026

Quarterly net margin

14.1%

Latest quarter · Q2 2026

Numbers and valuation

Full valuation
Market cap
CHF 44.63B
P/E
66.0
EPS
CHF 2.90
Volume
475.02K
Daily trading
€105.05M
Dividend yield
0.18%
Last ex-dividend on April 24, 2026

How Galderma Group is changing

All results
  • Revenue grew 11.1% a year on average over the last 3 years

  • Operating margin rose from 10.5% to 16.9%

  • Profits turn into cash: free cash flow equal to 188% of net income

Returns

Galderma Group returns with dividends

CHF 1,000 invested in Galderma Group 1 year ago, on November 17, 2025, would be worth CHF 1,317 today with dividends reinvested: +31.70% in total, +31.70% per year. On price alone it would be CHF 1,314 (+31.42%).

PeriodGalderma GroupSMICHF 1,000 becomes
1 month+9.29%+8.46%CHF 1,093
6 months+22.82%+14.27%CHF 1,228
Year to date+18.69%+13.86%CHF 1,187
1 year+31.70%+19.91%CHF 1,317

Over the last 6 months it has done better than 36% of the stocks in the Healthcare sector.

From 1 year up with dividends reinvested, before taxes; under a year price only. SMI: price only. Calculate your investment

The chart in detail

Galderma Group: technical analysis

Galderma Group is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 1.4% below its all-time closing high (CHF 195.15, November 5, 2026).

Trend
Upward
RSI (14 sessions)
61
Between 30 and 70
vs 200-session average
+16.43%

Support and resistance

Price areas where Galderma Group has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. No resistance above: the price is near the highs of the year
  2. Last priceCHF 192.40
  3. SupportCHF 183.97−4.38%2 touches, last on August 7, 2026
  4. SupportCHF 170.79−11.23%5 touches, last on September 30, 2026
  5. SupportCHF 167.02−13.19%6 touches, last on August 18, 2026

Volatility and risk

Over the last year it has moved roughly in line with the SMI.

Beta (1 year) vs SMI
0.92
Volatility (60 sessions, annualised)
29.1%
Largest fall in the last year
−17.49%

In session, November 16, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

The company

Galderma Group and its competitors

Restylane, Dysport, Azzalure and Sculptra are among the injectable aesthetics brands people know best, while Cetaphil and ALASTIN cover dermatological skincare and Soolantra, Epiduo and Differin serve therapeutic dermatology. Galderma Group AG works across the dermatology market worldwide, offering aesthetic injectables, skincare products and treatments for skin conditions. Its portfolio also includes Oracea, AKLIEF, NEMLUVIO and Relfydess, and the company provides services alongside its brands. Its therapeutic range also includes Loceryl, Benzac and Metvix.

Headquarters
Zug, Switzerland
Employees
7,676
Founded
1981
Chief executive
Flemming Ornskov
Galderma Group and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
Galderma GroupGALD$53.24B19.1%66.0+22.82%
Sandoz GroupSDZ$43.66B9.3%72.3+30.60%
HaleonHLN$40.03B23.5%19.2+4.51%
MerckMRK$71.89B17.0%33.8+28.50%
Swedish Orphan BiovitrumSOBI$16.42B30.9%25.0+8.39%
IpsenIPN$15.16B27.4%26.9+0.60%

Same industry or related industries, similar size. Compare Galderma Group with its competitors · Full profile